Interest Rates and mREITs: With interest rates expected to decline under new Fed leadership, mortgage REITs like Annaly Capital and Dynex Capital are positioned to benefit significantly, offering high dividend yields and potential for price appreciation as mortgage spreads ease.
AI in Drug Development: The integration of AI in pharmaceuticals is set to revolutionize drug discovery, reducing development cycles from 10-15 years to potentially 3-6 years, leading to increased profits and more drug candidates reaching the market.
Danaher's Role in Pharma: Danaher, a key supplier in life sciences, is well-positioned to benefit from the surge in pharmaceutical research driven by AI, as it provides essential tools and consumables needed for drug development, while also enjoying a strong dividend growth.
Hershey's Resilience: Despite challenges from rising cocoa prices, Hershey Foods has maintained its market dominance and is poised for recovery, having implemented efficiency measures and raised prices, which positions it well for future dividend growth.
Wall Street analysts forecast NLY stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for NLY is 22.00 USD with a low forecast of 20.00 USD and a high forecast of 23.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
Wall Street analysts forecast NLY stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for NLY is 22.00 USD with a low forecast of 20.00 USD and a high forecast of 23.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
3 Hold
0 Sell
Moderate Buy
Current: 23.830
Low
20.00
Averages
22.00
High
23.50
Current: 23.830
Low
20.00
Averages
22.00
High
23.50
Barclays
Equal Weight
maintain
$20 -> $23
Al Analysis
2026-01-06
Reason
Barclays
Price Target
$20 -> $23
Al Analysis
2026-01-06
maintain
Equal Weight
Reason
Barclays raised the firm's price target on Annaly Capital to $23 from $20 and keeps an Equal Weight rating on the shares. The firm sees additional upside in select consumer finance name in 2026. A "benign' credit environment sets the stage for loan growth, the analyst tells investors in a research note. Barclays also forecasts a better mortgage origination market in 2026. The firm adjusted price targets as part of its 2026 outlook.
Piper Sandler
Piper Sandler
Overweight
maintain
2025-12-22
Reason
Piper Sandler
Piper Sandler
Price Target
2025-12-22
maintain
Overweight
Reason
Piper Sandler raised the firm's price target on Annaly Capital to $23.50 from $22.50 and keeps an Overweight rating on the shares ahead of Q4 results for the firm's mortgage finance coverage. The sector backdrop has shifted positively, driven by 30-year rates falling to 6.2% from 7%-plus highs earlier in the year and material tightening in agency spreads. While the market has not yet fully "normalized," momentum is building, Piper argues. Mortgage application volumes are rising, led by an 18% sequential and 100%-plus year-over-year surge in refinance activity. Additionally, GSE reform is likely to return to the spotlight given the administration's push for a deal under President Trump and FHFA Director Bill Pulte, it adds.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for NLY
Unlock Now
Keefe Bruyette
Outperform
maintain
2025-12-18
Reason
Keefe Bruyette
Price Target
2025-12-18
maintain
Outperform
Reason
Keefe Bruyette raised the firm's price target on Annaly Capital to $23.25 from $22.50 and keeps an Outperform rating on the shares. The firm remains most constructive on the agency MBS REITs heading into 2026, the analyst tells investors in a research note.
JPMorgan
Richard Shane
Overweight
maintain
$21 -> $22
2025-10-20
Reason
JPMorgan
Richard Shane
Price Target
$21 -> $22
2025-10-20
maintain
Overweight
Reason
JPMorgan analyst Richard Shane raised the firm's price target on Annaly Capital to $22 from $21 and keeps an Overweight rating on the shares as part of a Q3 preview for the mortgage real estate investment trust group. Uncertainty around the path of interest rates is "quickly diminishing" but inflation remains a risk, the analyst tells investors in a research note. JPMorgan believes a steeper yield curve will be a tailwind for residential mortgage REITS but may have a more measured impact on commercial REITs.
About NLY
Annaly Capital Management, Inc. is a diversified capital manager with investment strategies across mortgage finance. It owns a portfolio of real estate related investments, including mortgage pass-through certificates, collateralized mortgage obligations, credit risk transfer (CRT) securities, and other securities representing interests in or obligations backed by pools of mortgage loans, residential mortgage loans and mortgage servicing rights. Its investment groups include Annaly Agency Group, Annaly Residential Credit Group, and Annaly Mortgage Servicing Rights Group. Annaly Agency Group invests in agency mortgage-backed securities collateralized by residential mortgages. Annaly Residential Credit Group invests in non-agency residential mortgage assets within residential and commercial markets. Annaly Mortgage Servicing Rights Group invests in MSR, which provides the right to service residential mortgage loans in exchange for a portion of the interest payments made on the loans.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
